The Effect of Fimasartan, an Angiotensin Receptor Type 1 Blocker, on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Korean Male Volunteers: A One-Sequence, Two-Period Crossover Clinical Trial

Clinical Therapeutics

Volumn 34, Issue 7, 2012, Pages 1592-1600

  Gu, Namyi ^a   Kim, Bo Hyung ^a   Lim, Kyoung Soo ^a   Kim, Sung Eun ^a   Nam, Won Seok ^a   Yoon, Seo Hyun ^a   Cho, Joo Youn ^a   Shin, Sang Goo ^a   Jang, In Jin ^a   Yu, Kyung Sang ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Drug interaction; Fimasartan; Pharmacodynamics; Pharmacokinetics; Warfarin

Indexed keywords

FIMASARTAN; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG LABELING; DRUG MARKETING; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EPISTAXIS; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL NORMALIZED RATIO; KOREA; LABORATORY TEST; MALE; MORNING DOSAGE; NORMAL HUMAN; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTICOAGULANTS; AREA UNDER CURVE; BIPHENYL COMPOUNDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; PYRIMIDINES; REPUBLIC OF KOREA; STEREOISOMERISM; TANDEM MASS SPECTROMETRY; TETRAZOLES; WARFARIN; YOUNG ADULT;

EID: 84863856493     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.06.004     Document Type: Article

References (34)

1. Chi Y.H., Lee H., Paik S.H., et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects. Am J Cardiovasc Drugs 2011, 11:335-346.
2. Lee S.E., Kim Y.J., Lee H.Y., et al. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, Phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. Clin Ther 2012, 34:552-568.
3. Barreras A., Gurk-Turner C. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent) 2003, 16:123-126.
4. Fimasartan. Am J Cardiovasc Drugs 2011, 11:249-252.
5. Shin K.H., Kim T.E., Kim S.E., et al. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers. J Cardiovasc Pharmacol 2011, 58:492-499.
6. Kim J.W., Yi S., Kim T.E., et al. Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. J Clin Pharmacol 2012 Jan 26, [Epub ahead of print].
7. Yi S., Kim T.E., Yoon S.H., et al. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharmacol 2011, 57:682-689.
8. Jeon H., Lim K.S., Shin K.H., et al. Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers. J Cardiovasc Pharmacol 2012, 59:84-91.
9. Yi S., Kim J.W., Kim T.E., et al. Effect of multiple doses of fimasartan, an angiotensin II receptor antagonist, on the steady-state pharmacokinetics of digoxin in healthy volunteers. Int J Clin Pharmacol Ther 2011, 49:321-327.
10. Tadros R., Shakib S. Warfarin-indications, risks and drug interactions. Aust Fam Physician 2010, 39:476-479.
11. Hirsh J., Poller L. The international normalized ratio. A guide to understanding and correcting its problems. Arch Intern Med 1994, 154:282-288.
12. Nutescu E.A., Shapiro N.L., Ibrahim S., West P. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 2006, 5:433-451.
13. Holbrook A.M., Pereira J.A., Labiris R., et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005, 165:1095-1106.
14. Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects, 55th WMA General Assembly, Tokyo 2004 World Medical Association, Accessed June 20, 2011. http://www.wma.net/en/30publications/10policies/b3/17c.pdf.
15. Guideline for Good Clinical Practice E6 (R1) Step 4 version, ICH Harmonised Tripartite Guideline, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Accessed June 20, 2011. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf.
16. Jung T.R., Hwang S.W., Lee J.U., et al. Comparative consistency between obesity determination standards using body mass index and ideal body weight. J Korean Acad Fam Med 2001, 22:1765-1771.
17. Coe R.A., Rathe J.O., Lee J.W. Supercritical fluid chromatography-tandem mass spectrometry for fast bioanalysis of R/S-warfarin in human plasma. J Pharm Biomed Anal 2006, 42:573-580.
18. Ring P.R., Bostick J.M. Validation of a method for the determination of (R)-warfarin and (S)-warfarin in human plasma using LC with UV detection. J Pharm Biomed Anal 2000, 22:573-581.
19. Gabrielsson J., Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis, Concepts and Applications 2007, CRC Press, Boca Raton, Fla. 4th ed.
20. 33rd Report, WHO Technical Report Series 687 1983, 81-105. WHO Expert Committee on Biological Standardization, WHO, Geneva, Accessed June 20, 2011. http://www.wma.net/en/30publications/10policies/b3/17c.pdf.
21. Tripodi A., Chantarangkul V., Negri B., et al. International collaborative study for the calibration of a proposed reference preparation for thromboplastin, human recombinant, plain. On behalf of the Subcommittee on Control of Anticoagulation. Thromb Haemost 1998, 79:439-443.
22. Almeida L., Falcao A., Vaz-da-Silva M., et al. Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Eur J Clin Pharmacol 2008, 64:961-966.
23. Soon D., Kothare P.A., Linnebjerg H., et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol 2006, 46:1179-1187.
24. Hirsh J., Fuster V., Ansell J., Halperin J.L. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003, 107:1692-1711.
25. Bonate P.L., Howard D.R. Pharmacokinetics in Drug Development. Volume 1: Clinical Study Design and Analysis 2004, AAPS Press, Arlington, VA.
26. Zhou H., Patat A., Parks V., et al. Absence of a pharmacokinetic interaction between etanercept and warfarin. J Clin Pharmacol 2004, 44:543-550.
27. Jiang X., Williams K.M., Liauw W.S., et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2005, 59:425-432.
28. Zimmerman J.J., Raible D.G., Harper D.M., et al. Evaluation of a potential tigecycline-warfarin drug interaction. Pharmacotherapy 2008, 28:895-905.
29. Ried L.D. Science snippets. Clopidogrel and PPI, warfarin management, and rural pharmacists' competence. J Am Pharm Assoc (2003) 2010, 50:552.
30. Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic Therapy in Atrial Fibrillation: Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:546S-592S.
31. Jindal D., Tandon M., Sharma S., Pillai K.K. Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects. Eur J Clin Pharmacol 2005, 61:621-625.
32. Dingemanse J., Meyerhoff C., Schadrack J. Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol 2002, 53:485-491.
33. Miller J.W., Skerjanec A., Knadler M.P., et al. Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin. Pharm Res 2001, 18:1024-1028.
34. Lee H.W., Lim M.S., Seong S.J., et al. Effect of age on the pharmacokinetics of fimasartan (BR-A-657). Expert Opin Drug Metab Toxicol 2011, 7:1337-1344.